文献速递内脏/肾动脉与血管畸形

纤维肌性发育不良所致肾动脉狭窄的血管内治疗结局:系统综述与荟萃分析

Outcomes Following the Endovascular Treatment of Renal Artery Stenosis Caused by Fibromuscular Dysplasia: A Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Vasc Surg · 2021-09-17

该系统综述与荟萃分析共纳入36项研究、1191例患者共1916次修复,评估血管内成形术治疗纤维肌性发育不良所致肾动脉狭窄合并高血压的结局。总体技术成功率94.3%,总并发症率12.9%,高血压治愈率37.0%、改善率80.0%,但采用现行治愈定义时治愈率仅18.1%,且治愈率随患者平均年龄和高血压病程增加而显著下降。

要点

  • 血管内治疗技术成功率高(94.3%),但并发症率12.9%,其中主要并发症4.6%。
  • 高血压改善率80.0%,但治愈率仅37.0%;采用现行定义(血压<140/90 mmHg且无需治疗)时治愈率仅18.1%。
  • 患者平均年龄每增加10岁及高血压病程每增加5年,均与治愈率显著下降相关。

核心结论

  • 血管内治疗对纤维肌性发育不良所致肾动脉狭窄患者带来中等获益,但各研究间差异较大。
  • 血压结局受患者年龄强烈影响。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase和Cochrane对照试验中心注册库至2020年1月15日。
  • 共纳入36项研究(33项回顾性、3项前瞻性),涉及1191例患者、1916次修复。

主要发现

  • 总体技术成功率为94.3%。
  • 总并发症率、主要并发症率和次要并发症率分别为12.9%、4.6%和7.4%。
  • 高血压治愈率和改善率分别为37.0%[95%CI: 27.0%-47.0%]和80.0%[95%CI: 75.0%-84.0%],但研究间异质性高。
  • 采用现行治愈定义(血压<140/90 mmHg且无需治疗)的研究中,治愈率仅为18.1%。
  • 治愈率随患者平均年龄增加而下降(平均年龄每增加10年的OR为-0.24[95%CI: -0.44至-0.04,P=0.019]),随高血压平均病程增加而下降(病程每增加5年的OR为-0.09[95%CI: -0.12至-0.05,P=0.001])。

临床怎么用

  • 血管内治疗可用于纤维肌性发育不良所致肾动脉狭窄合并高血压患者,但应充分评估年龄和高血压病程对治愈可能性的影响。
  • 与患者沟通时需说明技术成功率高但治愈率有限,尤其对年龄较大或高血压病程较长者。

局限性

  • 纳入研究以回顾性为主(33/36),可能存在选择偏倚和异质性。
  • 高血压治愈和改善的定义在各研究间存在差异,影响结果可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Renal artery revascularization has been performed to improve blood pressure control and to cure hypertension in patients with renal artery fibromuscular dysplasia (RAFMD). We herein conducted a systematic review and meta-analysis of studies assessing outcomes associated with the treatment of hypertensive RAFMD patients via endovascular angioplasty in order to offer an up-to-date overview of the relative costs and benefits of this approach to revascularization in RAFMD patients. METHODS: We systematically searched the PubMed and Embase databases and the Cochrane Central Register for Controlled Trials to identify relevant studies published as of January 15, 2020. Key outcomes of interest in these studies included technical success, the incidence of perioperative complications, cure rates, and overall improvement rates. RESULTS: In total, we identified 36 relevant studies of 1916 total repairs conducted in 1191 patients. Of these included studies, 33 were retrospective, while 3 were prospective. The overall technical success rate across these studies was 94.3%. Rates of total, major, and minor complications in these pooled studies were 12.9%, 4.6%, and 7.4%, respectively. Pooled rates of cured hypertension and improved hypertension following angioplasty, defined according to study-specific criteria, were 37.0% [95% CI: 27.0%-47.0%] and 80.0% [95% CI: 75.0% to 84.0%], respectively, although these rates varied highly among studies. Cure rates for studies used current clinical definitions for substantial variations across studies. Cure rates in studies using current definitions of cured hypertension (blood pressure <140/90 mm Hg without treatment) were just 18.1% following angioplasty. Cure rates fell markedly with increasing mean patient age (OR associated with an increase in mean age of 10 years: -0.24 [95% CI: -0.44 to -0.04, P = 0.019] and with mean known duration of hypertension (OR associated with an increase in mean hypertension duration of 5 years: -0.09 [95% CI: -0.12 to -0.05, P = 0.001]). CONCLUSIONS: These findings suggest that endovascular treatment yielded moderate benefits to RAFMD patients, with substantial variation across studies. The blood pressure outcome was strongly influenced by patient age.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tian Y, Yuan B, Zhang N, et al. Outcomes Following the Endovascular Treatment of Renal Artery Stenosis Caused by Fibromuscular Dysplasia: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2021. PMID: 34543714. doi:10.1016/j.avsg.2021.06.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。